Lipids and Cardiovascular Risk Through the Lens of Rheumatoid Arthritis
- PMID: 30983150
- DOI: 10.1002/art.40891
Lipids and Cardiovascular Risk Through the Lens of Rheumatoid Arthritis
Comment on
-
A Multicenter, Randomized, Placebo-Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis.Arthritis Rheumatol. 2019 Sep;71(9):1437-1449. doi: 10.1002/art.40892. Epub 2019 Jul 22. Arthritis Rheumatol. 2019. PMID: 30983166 Free PMC article. Clinical Trial.
References
-
- Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB Sr, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2935-59.
-
- Crowson CS, Matteson EL, Roger VL, Therneau TM, Gabriel SE. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol 2012;110:420-4.
-
- Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
-
- Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary-a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018. E-pub ahead of print.
-
- Kitas GD, Nightingale P, Armitage J, Sattar N, Belch JJ, Symmons DP, on behalf of the TRACE RA Consortium. A multicenter, randomized, placebo-controlled trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheumatol 2019;71:1437-49.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
